Category Archives: R&D

How We Fall into Clinical Trial Metrics Malpractice

Effective clinical trial management depends on accurate and unbiased performance measurement. Performance measures are the lens through which managers monitor clinical trials and assess trial quality. Using the wrong metric or having biased measures distorts managers’ view and hinders effective trial oversight. It is important, then, that clinical trials managers make sure that they are […]
Also posted in Guest Blog | Tagged , | Leave a comment

Pharm Exec's Brands of Yesteryear: Where Are They Now?

Pharm Exec’s Brand of the Year selections from the last few years are still alive and kicking, although some have aged more gracefully than others. The US drug pricing wars may be coming, but these products already made their mint. We checked back in with them to see how things are going, and to look […]
Also posted in Pharm Exec Magazine, Strategy | Tagged , , , , , , | Leave a comment

Paying for the Future of Medicine

Is the hallmark of innovation higher drug prices? The three leading justifications for sticker-shocking drug prices in the US, from the biopharma perspective, are: 1) it costs a lot to bring a drug to market;* 2) drugs – even very expensive ones – are cheaper in the long run since they prevent complications, hospitalizations and […]
Also posted in Biotech, FDA, healthcare, leadership, Manufacturing, Market Access, pricing, Regulatory, Technology | Tagged , , , , , , | 1 Comment

Vaccine Demand Spurs Innovation

Vaccine development is on a roll, boosted by biomedical research uncovering new molecular targets for preventives and treatments, as well as innovative techniques for enhancing vaccine potency and production. There is high demand for new vaccines to prevent deadly tropical diseases, illustrated by the recent Ebola virus outbreak, and for capacity to respond quickly to […]
Also posted in Regulatory | Tagged , , | Leave a comment

Eight Ingredients for a Successful Oncology Drug Development Recipe

by Matthew Cook and Sebastien Morisot In light of the risks and challenges inherent in the development of oncologics, some biopharma companies are beginning to question whether oncology remains an attractive therapeutic area in which to invest limited research, development, and commercialization resources.
Also posted in Agency Insight, Biotech, Europe, FDA, Gene therapy, Guest Blog, leadership, Market Access, Orphan Drugs, pricing, Regulatory, Sales | Tagged , , | Leave a comment
  • Categories

  • Meta